Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methadone + dexmedetomidine + ketamine
- Development stage
- Unknown
- Lead developer
- University of Missouri-Columbia
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The combination of methadone, dexmedetomidine, and ketamine, often referred to as the MDK regimen, is a multimodal analgesic approach being investigated by the University of Missouri-Columbia for the management of postoperative pain in patients undergoing complex spine surgeries. This combination therapy leverages the distinct pharmacological profiles of its three components to target multiple pain pathways. Methadone acts as a long-acting mu-opioid receptor agonist and an NMDA receptor antagonist; dexmedetomidine is a highly selective alpha-2 adrenergic agonist with sedative and analgesic properties; and ketamine serves as a non-competitive NMDA receptor antagonist. By utilizing these agents in tandem, the regimen aims to provide superior intraoperative and postoperative pain control while significantly reducing the requirement for supplemental opioid medications, thereby potentially minimizing opioid-related side effects and improving patient recovery outcomes.
- Other names
- Methadone-dexmedetomidine-ketamine combinationMDK combination
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)ADRA2C (α2C)MOR (Mu opioid receptor)ADRA2A (α2A)
Beyond the preview
Go deeper on methadone + dexmedetomidine + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methadone + dexmedetomidine + ketamine.